Drug Profile
Research programme: anticancer monoclonal antibodies - Recepta biopharma
Alternative Names: Anti-LeB antibody; mAb 58-1066; mAb A34; mAb MX35; Monoclonal antibody 58-1066 - Anti-LeB; Monoclonal antibody A34 (209-342); Monoclonal antibody MX35; RebmAb-300; RebmAb-400; RebmAb-500Latest Information Update: 11 Jan 2023
Price :
$50
*
At a glance
- Originator Ludwig Institute for Cancer Research
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Lewis blood group system modulators; Type-IIb sodium-phosphate cotransporter protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 06 Jan 2023 Preclinical development is still ongoing for Cancer in Brazil (http://www.receptabio.com.br/en/pesquisa-desenvolvimento/anticorpos-monoclonais-recepta-detem-potencial-para-tratar-diversos-tipos-de-cancer/)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in Brazil
- 23 Oct 2018 Preclinical development is ongoing in Brazil (Recepta biopharma pipeline, October 2018)